{
    "clinical_study": {
        "@rank": "73878", 
        "arm_group": [
            {
                "arm_group_label": "Symbicort", 
                "description": "BFC patients new to ICS/LABA and LAMA therapies"
            }, 
            {
                "arm_group_label": "Spiriva", 
                "description": "Tiotropium bromide patients new to ICS/LABA and LAMA therapies"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is intended to evaluate treatment effectiveness with budesonide/formoterol (BFC)\n      and tiotropium tromide in patients new to ICS/LABA combination and LAMA therapies."
        }, 
        "brief_title": "Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "COPD Exacerbation", 
        "condition_browse": {
            "mesh_term": "Pulmonary Disease, Chronic Obstructive"
        }, 
        "detailed_description": {
            "textblock": "Using US claims data from the HealthCore Integrated Research Environment, COPD patients \u226540\n      years old initiating BFC or tiotropium between 3/1/2009-2/28/2012 and considered at risk for\n      a future exacerbation were identified and followed for 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Continuous health plan enrollment for 12 months before and after   index Rx\n\n          -  At least one prescription fill for BFC or tiotropium bromide during intake period,\n             and naive to ICS/LABA combination or LAMA therapies in year prior to first\n             prescription claim.\n\n          -  COPD diagnosis, and aged 40 years of age at time of first prescription\n\n          -  At risk population for COPD exacerbations\n\n        Exclusion Criteria:\n\n          -  ICS/LABA combination or LAMA therapy during pre-index period\n\n          -  Patients with prescription claim for budesonide/formoterol and tiotropium bromide on\n             the same day\n\n          -  Patients diagnosed with cancer\n\n          -  Patients with long-term OCS medication use during pre-index period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Health plan members with COPD aged 40 years or older receiving one or more prescriptions\n        of BFC or tiotropium bromide during 3/1/2009 and 1/31/2012 who are naive to ICS/LABA and\n        LAMA combination therapies."
            }
        }, 
        "enrollment": {
            "#text": "2396", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917643", 
            "org_study_id": "000202", 
            "secondary_id": "000202"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Tiotropium", 
                "Symbicort"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "COPD, Comparative Effectiveness, Symbicort", 
        "lastchanged_date": "February 25, 2014", 
        "number_of_groups": "2", 
        "official_title": "A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol (BFC) and Tiotropium Bromide Among COPD Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "RWE studies: Not applicable", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The time to first COPD exacerbation will be calculated as the date of first COPD exacerbation minus index date. A COPD exacerbation event is defined as any of three conditions: COPD related inpatient hospitalization, COPD related emergency department visit, or COPD outpatient/office visit with a pharmacy claim for OCS and/or antibiotics on the same day or within ten days.", 
            "measure": "Time to first COPD exacerbation", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917643"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The rate of COPD exacerbation will be defined as the total number of COPD exacerbations during the post-index period for all patients in each treatment cohort divided by the total number of person years.", 
                "measure": "COPD exacerbation rates", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "COPD respiratory medication use", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "COPD related outpatient/office visit, COPD related inpatient hospitalization length of stay , COPD related ICU admission and length of stay, COPD procedures.", 
                "measure": "COPD related utilization", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Frequency of all-cause resource use of: inpatient hospitalizations and length of stay, ICU admissions and length of stay, and outpatient/office visits. Total number of different prescription medication classes filled will also be determined.", 
                "measure": "All-cause utilization", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Costs will be reported for the following resource uses:  inpatient hospitalizations, ED visits, outpatient/office visits, skilled nursing facility, total medical, and prescriptions. Costs will be reported for all-cause as well as COPD related.", 
                "measure": "All-cause and COPD related healthcare costs", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Continuity of care during the 12 month post-index period will be measured with the Bice and Boxerman index.  Proportion of Days Covered (PDC) and Medication Possession Ration (MPR) will be used to measure the compliance of index medication (Symbicort or Spiriva) during the 12 month post-index period.", 
                "measure": "Treatment patterns and adherence", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "COPD medication use, such as treatment changes, will be captured post-index.", 
                "measure": "Treatment modification", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "HealthCore, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}